Clinical Oncology Next Generation Sequencing Market Growing to Unveil a Remarkable CAGR of 15.1%, Trends Industry Analysis, Top Manufacturers, Growth, Opportunities & Forecast 2029

An international Clinical Oncology Next Generation Sequencing Market research report provides information about all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands while giving a synopsis of market definition, classifications, and market trends. The report defines CAGR value fluctuations during the forecast period of 2022-2029 for the market. By knowing the marketing strategies of rivals, businesses can decide upon innovative ideas and striking sales targets. The data mentioned in the persuasive Clinical Oncology Next Generation Sequencing Market document also makes customers or other market participants attentive about the problems they may face while operating in this market over a longer period of time.

The market study carried out in the finest Clinical Oncology Next Generation Sequencing Market report analyzes the market status, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis. Moreover, analysis and estimation of important industry trends, market size, and market share are also covered in this market report. Clinical Oncology Next Generation Sequencing Market research report forecasts the size of the market with respect to the information on main retailer revenues, development of the Healthcare industry by upstream and downstream, industry progress, key companies, along with market segments and application.

Data Bridge Market Research analyses that the clinical oncology next generation sequencing market which was USD 592.56 million in 2021, would rocket up to USD 1825.30 million by 2029, and is expected to undergo a CAGR of 15.1% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Visit full Study Report @ https://www.databridgemarketresearch.com/reports/global-clinical-oncology-next-generation-sequencing-market

Next-generation sequencing is a DNA or RNA technique that permits several reactions to be carried out simultaneously. This is one of the most important applications of next-generation sequencing in oncology. In recent years, NGS has changed cancer genetics by providing researchers greater access to genomic and transcriptome data. Next-generation tumour and germline DNA sequencing is used in oncology screening for therapeutic application.

Clinical Oncology Next Generation Sequencing Market Dynamics
Drivers
• Increase in cancer cases
The clinical oncology next-generation sequencing market is projected to be significantly impacted by personalized medicine and oncology improvements. Rising cancer prevalence, high acceptance of sequencing-based diagnostics platforms among practicing oncologists, decrease in the cost of genetic sequencing, and increased government R&D funding are some of the reasons expected to boost market growth. On the other hand, high adoption of this technique over single-gene testing and higher adoption of clinical oncology next-generation sequencing technology and platforms in academia projects will fuel a slew of new opportunities, propelling the clinical oncology next generation sequencing market forward from 2022 to 2029.

• New technological Innovatives
According to the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), cancer was the top cause of death worldwide in 2020, with over 10 million fatalities. In addition, 19.3 million additional cases were reported globally. New creative technologies, such as next generation sequencing, are being used to address this worldwide burden and lower mortality rates. As a result, the clinical oncology next generation market is growing at a faster rate.
• Reduction in the cost of NGS platforms
The factor aiding the market's growth is the reduction in the cost of NGS platforms. Clinical oncology next-generation sequencing approaches provide a high percentage of reads as well as low cost per read. Leading players are introducing low-cost sequencing approaches. Similarly, the worldwide clinical oncology next generation sequencing market will expand over the forecast period as more people use next generation sequencing for liquid biopsy.

Some of the major players operating in the clinical oncology next generation sequencing market are:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Agilent Technologies Inc. (U.S.)
• Myriad Genetics Inc. (U.S.)
• BGI (China)
• Perkin Elmer Inc. (U.S.)
• Foundation Medicine Inc. (U.S.)
• PacBio (U.S.)
• Oxford Nanopore Technologies plc. (U.K.)
• Paradigm Diagnostics Inc. (U.S.)
• Caris Life Sciences (Japan)
• Partek, Incorporated (U.S.)
• Eurofins Scientific (Luxembourg)
• Qiagen (Germany)

Recent Development

• In January 2022, Agendia, Inc., a global pioneer in breast cancer precision medicine, announced a multi-year collaboration with Illumina to co-develop in vitro diagnostic (IVD) assays for oncology testing.
• In October 2021, Roche introduced the AVENIO tumour tissue CGP kit to make tailored cancer research more accessible.

Global Clinical Oncology Next Generation Sequencing Market Scope

The clinical oncology next generation sequencing market is segmented on the basis of technology, workflow, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing and Resequencing Centrifuges

Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

Application

• Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

End-user

• Hospitals
• Clinics
• Laboratories

Browse More Reports

https://markettreports.blogspot.com/2023/09/interventional-neurology-devices.html

https://markettreports.blogspot.com/2023/09/dental-microsurgery-market-trends.html

https://markettreports.blogspot.com/2023/09/fetal-bovine-serum-market-trends.html

https://markettreports.blogspot.com/2023/09/north-america-medical-equipment.html

About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: - corporatesales@databridgemarketresearch.com

This release was published on openPR.